MOTIV BTK Randomized Controlled Trial
Condition: Critical Limb Ischemia · Sponsor: REVA Medical, Inc.
About this study
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (26)
| California Heart and Vascular Clinic | El Centro, California, United States | — |
| Mission Cardiovascular Research Institute | Fremont, California, United States | — |
| Adventist Health | St. Helena, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| ClinRe | Thornton, Colorado, United States | — |
| Vascular Care Connecticut | Darien, Connecticut, United States | — |
| First Coast Cardiovascular Institute | Jacksonville, Florida, United States | — |
| Miami Cardiac & Vascular Institute | Miami, Florida, United States | — |
| Palm Vascular | Miami Beach, Florida, United States | — |
| Piedmont Atlanta Hospital | Atlanta, Georgia, United States | — |
| Pacific Vascular Institute | ‘Aiea, Hawaii, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
+ 14 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05406622